US Corporate Distress Financial Stress SEC Filings — February 12, 2026

13-02-2026

AMC Entertainment Holdings, Inc. filed an 8-K on 2026-02-13 under Item 1.01 disclosing entry into a Material Definitive Agreement and under Item 9.01 providing Financial Statements and Exhibits. No specific details, transaction values, financial metrics, parties involved, or impacts are disclosed in the provided filing summary. No quantitative data or period-over-period comparisons are mentioned.

13-02-2026

W. P. Carey Inc. filed a Form 8-K on 2026-02-13 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, events, transaction values, financial metrics, or impacts disclosed in the provided information. No positive or negative metrics are mentioned.

13-02-2026

Nektar Therapeutics filed a Form 8-K on 2026-02-13 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on a material agreement and additional events, with exhibits attached. No financial metrics, transaction details, positive or negative impacts, or quantitative data are disclosed.

13-02-2026

SunHydrogen, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015747, Size: 380 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, parties, financial impacts, or other metrics are disclosed. This is a multi-item mandatory filing with no period-over-period comparisons or quantitative data provided.

13-02-2026

Immunic, Inc. filed a Form 8-K on 2026-02-13 disclosing multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details, transaction values, personnel names, share counts, or financial metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments but lacks quantitative data for impact assessment.

13-02-2026

Tri Pointe Homes, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific quantitative details, transaction sizes, financial impacts, or directional metrics disclosed. No positive or negative performance metrics are provided.

13-02-2026

BRAINSTORM CELL THERAPEUTICS INC. filed an 8-K on February 13, 2026 (AccNo: 0001104659-26-015262), reporting entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, accompanied by financial statements and exhibits under Item 9.01. No quantitative details such as transaction values, share counts, or financial impacts are disclosed. This multi-item filing signals a potentially significant financing or partnership event typical in biotech but lacks specifics on terms or effects.

• ·Filing Accession Number: 0001104659-26-015262
• ·File Size: 730 KB
• ·Multi-item mandatory 8-K filing

13-02-2026

Noodles & Co filed a Form 8-K on February 13, 2026, under Item 3.03 disclosing material modifications to rights of security holders, Item 5.03 reporting amendments to articles of incorporation or bylaws or a change in fiscal year, Item 8.01 for other events, and Item 9.01 for financial statements and exhibits. This is a multi-item filing with no quantitative financial metrics, transaction details, or performance comparisons provided. No positive or negative impacts are quantified in the available information.

13-02-2026

Evommune, Inc. filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), alongside Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). While the material agreement signals potential strategic advancement, the equity sales raise dilution concerns. No specific transaction values, terms, financial impacts, or quantitative details are disclosed.

13-02-2026

HCW Biologics Inc. filed an 8-K on February 13, 2026, disclosing entry into a Material Definitive Agreement under Item 1.01 and providing Financial Statements and Exhibits under Item 9.01. No details on the agreement's parties, terms, value, strategic rationale, or financial impacts are mentioned. This is a multi-item mandatory filing with no quantitative metrics, positive or negative changes, or performance comparisons provided.

13-02-2026

SAFE & GREEN HOLDINGS CORP. filed an 8-K on 2026-02-13 under Item 1.01 disclosing entry into a material definitive agreement and Item 9.01 for financial statements and exhibits. No details on the agreement's nature, parties, dollar value, strategic importance, or financial impacts are disclosed in the provided information. This is a multi-item mandatory filing likely made timely on the event date.

13-02-2026

Royal Caribbean Cruises Ltd filed an 8-K on February 13, 2026 (AccNo: 0001104659-26-014730), reporting under Item 1.01 entry into a material definitive agreement and Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This appears to be a multi-item mandatory filing with limited public summary information available.

• ·Filing size: 482 KB
• ·Sector: not specified

13-02-2026

Citius Pharmaceuticals, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001213900-26-015895), disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, and under Item 2.02 results of operations and financial condition. Item 9.01 references financial statements and exhibits. This multi-item filing highlights a material compliance failure with exchange listing requirements, with no specific financial metrics or performance details provided.

• ·Multi-item 8-K filing (Items 2.02, 3.01, 9.01)
• ·Event date aligns with filing date: 2026-02-13

13-02-2026

Columbus Circle Capital Corp II filed a Form 8-K on February 13, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details, transaction values, personnel names, financial metrics, or quantitative impacts are disclosed in the provided filing summary. This multi-item filing signals several corporate developments but lacks data for directional assessment.

13-02-2026

The registrant filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or an obligation under an off-balance sheet arrangement under Item 2.03. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, terms, or financial impacts are disclosed.

13-02-2026

Immersion Corp filed a Form 8-K on 2026-02-13 under Item 3.01 announcing a notice of delisting or failure to satisfy a continued listing rule or standard, along with transfer of listing. The filing also includes Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No financial metrics, transaction values, or other quantitative details are disclosed.

13-02-2026

Tennant Co filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement under Item 1.01, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements under Item 5.02, along with Regulation FD disclosure under Item 7.01 and financial statements/exhibits under Item 9.01. This is a multi-item mandatory filing with no specific transaction details, dollar values, or financial metrics provided. No positive or negative quantitative impacts, guidance changes, or operational metrics were disclosed.

13-02-2026

Marpai, Inc. filed an 8-K on 2026-02-13 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement). Item 9.01 includes Financial Statements and Exhibits. No quantitative details, transaction specifics, parties, dollar values, or impacts are disclosed.

13-02-2026

NEXTNRG, INC. filed an 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction terms, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This is a multi-item mandatory disclosure with no period-over-period comparisons or other numerical data available.

13-02-2026

Society Pass Incorporated filed an 8-K on February 13, 2026, disclosing under Item 1.01 entry into a material definitive agreement, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. No specific details on the agreement, events, transaction value, financial impacts, or quantitative metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments, but lacks context for directional assessment.

13-02-2026

Healthcare Triangle, Inc. filed an 8-K on February 13, 2026, disclosing events under Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details, financial metrics, transaction values, or directional impacts are provided in the filing summary. This appears to be a multi-item mandatory filing with no quantified positive or negative changes disclosed.

13-02-2026

Jet.AI Inc. filed a multi-item Form 8-K on February 13, 2026 (AccNo: 0001493152-26-006713), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details, transaction values, financial metrics, or impacts are disclosed in the provided filing summary. No quantitative data, period-over-period comparisons, or scheduled events are mentioned.

• ·Multi-item 8-K filing indicating multiple corporate actions
• ·Filing size: 882 KB

13-02-2026

Intensity Therapeutics, Inc. filed a Form 8-K on February 13, 2026, reporting multiple items: Item 3.03 on material modifications to rights of security holders, Item 5.03 on amendments to articles of incorporation or bylaws or change in fiscal year, Item 8.01 on other events, and Item 9.01 on financial statements and exhibits. No specific details, transaction values, financial metrics, positive or negative changes, or numerical data are disclosed in the provided filing summary. This is a multi-item informational filing with no disclosed impacts on revenue, earnings, balance sheet, or guidance.

13-02-2026

Huntsman Corp filed a Form 8-K on February 13, 2026, reporting entry into a new material definitive agreement under Item 1.01 while simultaneously disclosing termination of a prior material definitive agreement under Item 1.02; however, it also announced creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. Item 9.01 provides financial statements and exhibits. This multi-item filing signals significant contractual and financial changes, but no specific details, dollar values, or impacts are disclosed.

13-02-2026

Transact Technologies Inc filed an 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, or financial impacts are disclosed.

13-02-2026

Emerson Electric Co filed an 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are disclosed.

13-02-2026

TransDigm Group Inc filed an 8-K on February 13, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction values, financial impacts, or other quantitative details are disclosed.

13-02-2026

Envirotech Vehicles, Inc. filed an 8-K on February 13, 2026, reporting under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, including transfer of listing. Item 8.01 discloses other events. No financial metrics, quantitative data, or period-over-period comparisons provided.

13-02-2026

Martin Marietta Materials Inc filed an 8-K on February 13, 2026, disclosing under Item 1.04 mine safety matters involving reporting of shutdowns and patterns of violations. No additional quantitative details, financial impacts, or operational specifics were provided in the filing summary.

13-02-2026

Cencora, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, under Item 7.01 Regulation FD disclosure, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. This multi-item filing indicates significant corporate actions but provides no quantitative details on transaction size, financial impacts, or strategic context. No positive or negative metrics are disclosed.

13-02-2026

Nuvve Holding Corp. filed an 8-K on February 13, 2026, reporting under Item 1.02 the termination of a material definitive agreement, which represents a negative development. Item 9.01 discloses financial statements and exhibits. No quantitative financial impacts, transaction values, or strategic details are provided.

13-02-2026

CERO Therapeutics Holdings, Inc. filed a Form 8-K on February 13, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), 3.02 (Unregistered Sales of Equity Securities), 4.01 (Changes in Registrant's Certifying Accountant), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), and 9.01 (Financial Statements and Exhibits). No specific transaction values, financial metrics, named parties, or quantitative impacts are disclosed in the provided filing summary. This multi-item filing signals several operational and financial changes, but lacks details to assess directional impact.

13-02-2026

Pebblebrook Hotel Trust filed a Form 8-K on February 13, 2026, under Items 1.01 (Entry into a Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing signaling a significant agreement and new financial commitment, but no specific transaction details, dollar values, financial impacts, or metrics are disclosed. No positive or negative quantitative changes are mentioned.

13-02-2026

Red Robin Gourmet Burgers Inc filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement's nature, parties, terms, dollar value, or financial impacts are disclosed. No quantitative metrics, period-over-period comparisons, positive or negative changes, or operational data are provided in the filing summary.

13-02-2026

SmartKem, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001104659-26-015258), reporting under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. This indicates the company has been notified by its exchange of non-compliance with listing requirements. No financial metrics, transaction values, or additional details such as reasons for the notice or impacts were disclosed.

13-02-2026

Iveda Solutions, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001493152-26-006726), reporting entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific details on the agreement, events, dollar values, or financial impacts disclosed in the provided summary. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.

13-02-2026

FG Nexus Inc. filed an 8-K on February 13, 2026, disclosing under Item 3.03 material modifications to the rights of security holders and under Item 5.03 amendments to its articles of incorporation or bylaws or change in fiscal year. Item 9.01 includes financial statements and exhibits. No financial metrics, transaction details, or directional impacts are specified.

13-02-2026

Sysco Corp filed an 8-K on 2026-02-13 reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or obligation under an off-balance sheet arrangement under Item 2.03, with financial statements and exhibits provided under Item 9.01. No quantitative details such as transaction value, financial terms, or impacts on revenue, earnings, or balance sheet are disclosed. This is a multi-item mandatory disclosure of material events.

13-02-2026

Hyperscale Data, Inc. filed an 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 a Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific details, transaction terms, financial metrics, positive or negative impacts, or quantitative data are disclosed in the provided filing summary. This is a multi-item filing with no information on timing compliance relative to the event.

13-02-2026

Profusa, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-016496), reporting entry into a material definitive agreement under Item 1.01 and other events under Item 8.01. Item 9.01 discloses financial statements and exhibits. No specific details on the agreement terms, transaction value, financial impacts, or other events are provided.

13-02-2026

Phoenix Energy One, LLC filed a Form 8-K on February 13, 2026 (AccNo: 0001193125-26-051726), reporting under Item 1.01 entry into a Material Definitive Agreement. Item 9.01 includes Financial Statements and Exhibits. No specific terms, dollar values, strategic details, or financial impacts of the agreement are disclosed in the provided filing summary.

13-02-2026

Streamex Corp. filed a Form 8-K on February 13, 2026, disclosing under Item 1.02 the termination of a material definitive agreement, which signals a potentially negative development, while Item 5.02 reports departures of directors or certain officers alongside elections, appointments, and compensatory arrangements of certain officers, indicating leadership transitions. Item 8.01 covers other events and Item 9.01 includes financial statements and exhibits. This multi-item filing highlights significant corporate changes but provides no quantified financial impacts or further details.

13-02-2026

HELIX ENERGY SOLUTIONS GROUP INC filed an 8-K on 2026-02-13 disclosing entry into a Material Definitive Agreement under Item 1.01, accompanied by Financial Statements and Exhibits under Item 9.01. No specific transaction details, dollar values, financial impacts, positive or negative metrics, or period-over-period comparisons are disclosed in the provided filing summary.

13-02-2026

FLYEXCLUSIVE INC. filed a Form 8-K on February 13, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. This represents a multi-item mandatory filing with no specific details provided on the agreement's nature, parties, terms, value, or impacts. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.

• ·Sector: not specified

13-02-2026

Crypto Co filed an 8-K on February 13, 2026, disclosing entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, with financial statements and exhibits attached under Item 9.01. No specific transaction values, share counts, financial impacts, or other quantitative details are disclosed. This is a multi-item filing with no period-over-period comparisons or guidance changes mentioned.

13-02-2026

OXBRIDGE RE HOLDINGS Ltd filed an 8-K on February 13, 2026 (AccNo: 0001493152-26-006760), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits. No specific details on the agreement, transaction size, parties, financial impacts, or metrics are provided in the filing summary.

13-02-2026

BRC Inc. filed a Form 8-K on 2026-02-13 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, including potential transfer of listing. The filing also reports Regulation FD disclosure in Item 7.01 and attaches financial statements and exhibits in Item 9.01. No quantitative financial metrics, transaction values, or specific reasons for the delisting event are disclosed.

13-02-2026

ATN International, Inc. filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, accompanied by Regulation FD disclosure under Item 7.01 and exhibits under Item 9.01. No specific details on the nature of the agreement, transaction size, financial terms, or impacts are provided in the filing summary. This multi-item filing signals potentially significant but undisclosed corporate developments.

13-02-2026

Envoy Medical, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 8.01 other events, and Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement, events, transaction value, financial impacts, or quantitative metrics disclosed in the provided information. No positive or negative metrics, period-over-period changes, or guidance were mentioned.

13-02-2026

Charlie's Holdings, Inc. filed an 8-K on February 13, 2026, disclosing entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, with exhibits under Item 9.01. No specific details on the agreement terms, transaction value, share counts, or financial impacts are disclosed. This is a multi-item mandatory filing with no quantitative metrics provided.

13-02-2026

Funko, Inc. filed a Form 8-K on February 13, 2026, disclosing under Item 1.01 entry into a material definitive agreement. Item 9.01 reports financial statements and exhibits. No specific transaction details, dollar values, financial impacts, or performance metrics are disclosed.

13-02-2026

Wellgistics Health, Inc. filed a multi-item Form 8-K on February 13, 2026 (AccNo: 0001493152-26-006815, Size: 12 MB), reporting Item 1.01 Entry into a Material Definitive Agreement, Item 3.02 Unregistered Sales of Equity Securities, Item 7.01 Regulation FD Disclosure, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. No specific details, transaction values, financial metrics, or impacts are disclosed in the provided filing summary. This informational filing lacks quantitative data for assessing positive or negative implications.

13-02-2026

Banzai International, Inc. filed a Form 8-K on 2026-02-13 disclosing entry into a Material Definitive Agreement under Item 1.01, accompanied by Financial Statements and Exhibits under Item 9.01. No specific details on the agreement, transaction terms, financial impacts, or quantitative metrics are provided in the filing summary. No positive or negative performance metrics, comparisons, or other data are mentioned.

13-02-2026

IO Biotech, Inc. filed a Form 8-K on 2026-02-13 disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. This event signals potential removal from a US exchange, negatively impacting stock liquidity and accessibility for US investors. No financial metrics, quantitative impacts, or additional details such as dollar values or timelines were disclosed.